Replies to post #136324 on Biotech Values

[mcbio]

For those board members interested in cancer stem cells. Geron announced today the completion of enrollment in their phase II breast cancer study. They seem to have evolved from referring to the perviously referenced "cancer stem cell" to the perhaps less controversial "cancer progenitor cell" as the target for the agent imetelstat. This is said (by the company) to be the only anti cancer stem cell chemotherapeutic agent in clinical trials that targets this cell population (via telomerase inhibition). I posted previously about this but there was no interest so will not pursue on this board if no one (besides me) wants to discuss.

I don't believe GERN has yet to post any compelling clinical data on imetelstat have they? Please post if I'm wrong on that as I used to own GERN quite awhile ago but sold and don't follow as closely these days.